What is King Pharmaceuticals's all other lines — year 5?

King Pharmaceuticals (KG) reported all other lines — year 5 of 3.6% in Q4 2025.

What does all other lines — year 5 mean?

This metric tracks the financial results of secondary or miscellaneous business lines for the fifth fiscal year. It aggregates performance data from non-core operations that are not categorized within the company's primary reporting segments. Analyzing this data allows stakeholders to assess the stability and growth trajectory of the company's diversified business activities.

King Pharmaceuticals KG All other lines — Year 5

Other product segments

Commercial Auto Liability

14%—

General Liability

14%—

European Hospital Liability

11.9%—

International

-0.8%—

Similar metrics at other companies

ACGLMulti-line and other specialty — Year Five

5.6%+0.5pp

SKWDMulti-line Solutions — Year 5

10.5%+0.6pp

SPNTOther Specialties — Year 5

3.4%+1.7pp

SPNTOther — Year 5

2.5%-0.1pp

ACGLMulti-line and other specialty — Year Six

3.7%+0.4pp

SPNTOther — Year 10

0%—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearFive.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's all other lines — year 5.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's all other lines — year 5?: King Pharmaceuticals (KG) reported all other lines — year 5 of 3.6% in Q4 2025.
What does all other lines — year 5 mean?: This metric tracks the financial results of secondary or miscellaneous business lines for the fifth fiscal year. It aggregates performance data from non-core operations that are not categorized within the company's primary reporting segments. Analyzing this data allows stakeholders to assess the stability and growth trajectory of the company's diversified business activities.